You have 9 free searches left this month | for more free features.

ifosfamide and etoposide

Showing 1 - 25 of 1,033

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-Hodgkin's Lymphoma Trial in New York (Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin,

Completed
  • Non-Hodgkin's Lymphoma
  • Etoposide, carboplatin, ifosfamide
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 23, 2022

DLBCL (DLBCL) Trial (Glofitamab, Obinutuzumab, Tocilizumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Pembroke Pines, Florida
  • +3 more
Jan 23, 2023

Effect of Drug, Toxicity, Drug, Secondary Resistance Trial in Beijing (Apatinib Mesylate, ifosfamide and etoposide)

Completed
  • Effect of Drug
  • +2 more
  • Apatinib Mesylate
  • ifosfamide and etoposide
  • Beijing, Beijing, China
    Peking University People's Hospital
Mar 12, 2022

Classic Hodgkin's Lymphoma Trial in Beijing (Sintilimab, Carboplatin, Etoposide)

Recruiting
  • Classic Hodgkin's Lymphoma
  • Sintilimab
  • +4 more
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 12, 2022

Neuroblastoma, Pediatric Cancer Trial in New York (Cyclophosphamide, Topotecan, Vincristine)

Recruiting
  • Neuroblastoma
  • Pediatric Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 11, 2023

Effect of Drug, Drug, Toxicity Trial in Beijing (Apatinib+IE, IE)

Recruiting
  • Effect of Drug
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Mar 12, 2022

Aggressive Non-Hodgkin Lymphoma Trial in Belgium, France (drug, other, procedure)

Recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • Brugge, Belgium
  • +21 more
Jan 9, 2023

Testicular Cancer Trial in Houston, Seattle (Gemcitabine, Docetaxel, Melphalan)

Active, not recruiting
  • Testicular Cancer
  • Houston, Texas
  • +1 more
Dec 5, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Duarte, California
  • +3 more
Oct 24, 2022

B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • (no location specified)
Aug 7, 2023

Osteosarcoma Trial in China, Korea, Republic of (Sulfatinib, Etoposide, Isophosphamide)

Not yet recruiting
  • Osteosarcoma
  • Beijing, Beijing, China
  • +4 more
Oct 19, 2022

Mantle-Cell Lymphoma Trial in Miami (G-CSF, Rituximab, Cyclophosphamide)

Active, not recruiting
  • Mantle-Cell Lymphoma
  • G-CSF
  • +10 more
  • Miami, Florida
    University of Miami
Aug 12, 2021

Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

Not yet recruiting
  • Mature B-Cell Non-Hodgkin Lymphoma
  • (no location specified)
Sep 6, 2022

Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,

Terminated
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Miami, Florida
    University of Miami
Aug 23, 2022

Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

Recruiting
  • Lymphoma
  • Radiation Therapy
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

Relapsed Diffuse Large B-cell Lymphoma, Refractory DLBCL Trial in Worldwide (Polatuzumab Vedotin, Mabthera, Ifosfamide)

Recruiting
  • Relapsed Diffuse Large B-cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • +4 more
  • Graz, Austria
  • +62 more
Aug 2, 2022

Hodgkin Lymphoma Trial in Saint Petersburg, Irkutsk (Nivolumab, Ifosfamide, Carboplatin)

Recruiting
  • Hodgkin Lymphoma
  • Saint Petersburg, Pesochny, Russian Federation
  • +2 more
Jul 19, 2021

Diffuse Large B-cell-lymphoma Trial in Saint Louis, Cleveland (Venetoclax, Rituximab, Ifosfamide)

Active, not recruiting
  • Diffuse Large B-cell-lymphoma
  • Saint Louis, Missouri
  • +2 more
Nov 14, 2022

Effect of Drug, Toxicity, Drug Trial in Beijing (apatinib)

Recruiting
  • Effect of Drug
  • Toxicity, Drug
  • Beijing, Beijing, China
  • +1 more
Jul 12, 2021

Peripheral T-cell Lymphoma Trial in Singapore (Selinexor, ICE Chemotherapy)

Completed
  • Peripheral T-cell Lymphoma
  • Singapore, Singapore
    National Cancer Centre Singapore
Apr 27, 2021

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)

Active, not recruiting
  • CD20 Positive
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 11, 2021

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Intracranial Germ Cell CNS Tumor, Childhood Trial in Beijing (radiation, drug, procedure)

Recruiting
  • Intracranial Germ Cell CNS Tumor, Childhood
  • Whole-ventricle irradiation
  • +3 more
  • Beijing, China
    Beijing Tiantan Hospital
Nov 7, 2021

DLBCL Unclassifiable, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial in Duarte,

Recruiting
  • Diffuse Large B-Cell Lymphoma Unclassifiable
  • +6 more
  • Duarte, California
  • +1 more
Oct 1, 2021